This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Align Unveils Vivera Retainers for Deep Bite Correction
by Zacks Equity Research
Align (ALGN) hopes to taste greater clinical success in the orthodontic space with Vivera Retainers' integration into Precision Bite Ramps, which are part of the company's Invisalign G5.
Walgreens Boots' Retail Business Solid Amid Several Concerns
by Zacks Equity Research
Walgreens Boots (WBA) progresses with consistent sales rise in the Retail Pharmacy International business. Moreover, the stock grows on strategic alliances.
Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
by Zacks Equity Research
Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.
Walgreens Boots (WBA) Beats on Earnings in Q2, Lifts View
by Zacks Equity Research
Walgreens Boots (WBA) witnesses revenue growth across all three segments in Q2. A solid guidance instills investor confidence in the stock.
DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System
by Zacks Equity Research
DexCom (DXCM) is a leading player in the global CGM markets.
Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?
by Zacks Equity Research
Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.
3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
by Zacks Equity Research
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
Can Edwards Lifesciences (EW) Stock Continue to Grow Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Recent buyouts and CE Mark boost investors' confidence in Edwards Lifesciences (EW).
Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm
by Zacks Equity Research
Edward Lifesciences (EW) witnesses multiple developments in THV segment.
Markets Are Down, But These Stocks Surged to All-Time Highs Today
by Ryan McQueeney
Friday has been a rough day on Wall Street, with several major indexes--including the Dow, Nasdaq, and S&P 500--hovering deep in the red during early afternoon trading hours. Nevertheless, several notable stocks touched new all-time highs during the day. Check them out!
Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings
by Zacks Equity Research
Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.
Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio
by Zacks Equity Research
Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.
Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options
by Zacks Equity Research
Edwards Lifesciences (EW) needs investors to pay close attention to the stock based on moves in the options market lately.
EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?
by Zacks Equity Research
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q3 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve Therapy space.
Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Edwards Lifesciences, Bed Bath & Beyond, Annaly Capital Management, AGNC Investment and ARMOUR Residential REIT highlighted as Zacks Bull and Bear of the Day
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
The #1 non-surgical heart valve replacement technology owes its roots to a hydraulic pump engineer named Miles Edwards
Medtronic Advances in Pain Therapy With U.S. Intellis Launch
by Zacks Equity Research
We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).